Mission Therapeutics announces US FDA approval to initiate Phase II clinical trial of its lead asset MTX652 in Acute Kidney Injury
Mission gains clearance from US FDA for Phase II trial of MTX562 after it receives official approval of its Investigational New Drug (IND) application Phase II trial expected to begin Q1 2024 in up to 160 patients with acute kidney injury (AKI) following cardiac surgery CAMBRIDGE, England, Dec. 14,
Evermos Attains ISO 27001 Certification for Data Security Excellence
BANDUNG, Indonesia, Dec. 14, 2023 /PRNewswire/ — Evermos proudly announces its recent achievement of ISO 27001 certification for its Information Security Management System (ISMS), reaffirming the company’s commitment to delivering the highest standards of security across its entire platf
Wondershare Virbo Unveils AI-Powered Video Translator: Bridging Language Divides with Innovation
VANCOUVER, BC, Dec. 14, 2023 /PRNewswire/ — Wondershare Virbo, a leading AI avatar video creation platform, has recently unveiled a groundbreaking AI Video Translator feature. This innovative addition empowers users to swiftly translate their videos into multiple languages while seamlessly inc
SMEs Rebounding Strongly Amidst Economic Uncertainty
SME100 Participants More Than Doubled Revenue in 2022 KUALA LUMPUR, Malaysia, Dec. 14, 2023 /PRNewswire/ — Malaysian SMEs have experienced a significant rebound following the reopening of the economy post-COVID-19 pandemic. In 2022, the SME sector recorded an 11.6 percent growth in GDP against
Packaged Croissant Market is to grow by USD 1.85 billion from 2023 to 2028, Driven by the growing demand for convenience food – Technavio
NEW YORK, Dec. 13, 2023 /PRNewswire/ — The packaged croissant market is expected to grow by USD 1.85 billion from 2023 to 2028, according to Technavio. In addition, the growth momentum of the market will progress at a CAGR of 4.57% during the forecast period. Growing demand for convenience f
X0002: An Ibuprofenamine Hydrochloride Spray – Emerging Drug Insights and Market Forecasts to 2032
DUBLIN, Dec. 13, 2023 /PRNewswire/ — The “X0002 Emerging Drug Insight and Market Forecast – 2032” report has been added to ResearchAndMarkets.com’s offering. This report provides comprehensive insights about X0002 for osteoarthritis in the six major markets. A detail
BougeRV Arch launches new Max 270° bendable fiberglass Solar Panel with technological breakthrough
LOS ANGELES, Dec. 13, 2023 /PRNewswire/ — BougeRV, a world-class leading provider of outdoor appliances and the ultimate one-stop solution for all outdoor needs worldwide, today announced its new flexible 10BB solar panel, called the BougeRV Arch. This groundbreaking solar panel is the world&#
MainStreet Bank Promotes Tom Floyd to Executive Vice President
Chief Lending Officer Recognized for Breadth of Leadership Contribution FAIRFAX, Va., Dec. 13, 2023 /PRNewswire/ — MainStreet Bancshares, Inc. (Nasdaq: MNSB & MNSBP), the holding company for MainStreet Bank, promoted Tom Floyd to Executive Vice President. Floyd remains the Bank’s Ch
Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Myasthenia Gravis
The announcement follows the recent IND clearance for KYV-101 to be used in Kyverna’s KYSA-6 Phase 2 open-label, multicenter study KYV-101 is a fully human CD19 CAR T-cell therapy designed for use in patients with B cell-driven autoimmune diseases EMERYVILLE, Calif., Dec. 13, 2023 /PRNewswire/
UroMems Reaches Significant Milestone: Successful Results in Clinical Feasibility Study of UroActive™ Smart Implant for Stress Urinary Incontinence Treatment
Successful primary and secondary results demonstrate proof of feasibility in male patients, paving way for launch of large-scale pivotal clinical study in the U.S. and Europe GRENOBLE, France and MINNEAPOLIS, Dec. 13, 2023 /PRNewswire/ — UroMems, a global company developing innovative, mechatr